Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: A randomized, double-blind, placebo-controlled trial

被引:33
|
作者
Boon, R [1 ]
Goodman, JJ [1 ]
Martinez, J [1 ]
Marks, GL [1 ]
Gamble, M [1 ]
Welch, C [1 ]
机构
[1] SmithKline Beecham Consumer Healthcare, Res & Dev, Surrey KT10 0DE, England
关键词
penciclovir; herpes labialis; sunlight; symptoms; attributes;
D O I
10.1016/S0149-2918(00)87979-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The purpose of this study was to further define the therapeutic value of penciclovir cream in the treatment of sunlight-induced herpes labialis by comparing its efficacy and tolerability with those of an inactive control (purified water). Methods: In this randomized, double-blind, placebo-controlled, parallel-group clinical trial, lesions were induced by exposure to sunlight. Treatment was self-initiated within 1 hour of development of the signs or symptoms of a recurrence. Results: Healthy male and female patients (mean age, 38.3 years; range, 18 to 81 years) who had a history of sunlight-induced herpes labialis (mean of 6 recurrences in previous 12 months) applied either penciclovir cream (n = 266) or purified water (n = 275). Penciclovir cream significantly decreased the time to lesion healing (P < 0.001), with a reduction in median time of up to 2 days. The efficacy of penciclovir cream was further supported by a significant reduction in maximum lesion area (P = 0.008), a faster loss of lesion-associated symptoms (P = 0.026), and significant reductions in daily assessments of pain (P less than or equal to 0.040), itching (P less than or equal to 0.032), burning (P less than or equal to 0.028), and tenderness (P less than or equal to 0.026) as moderate or severe. These effects were reinforced by the results of the daily self-assessment of lesion attributes, with significantly fewer severe/extreme assessments of lesion size (P less than or equal to 0.003), noticeability (P less than or equal to 0.003), amount of scab/crust (P less than or equal to 0.003), raised/ swollen area (P less than or equal to 0.040), soreness/tenderness (P less than or equal to 0.043), and overall severity (P less than or equal to 0.001) throughout the study period. Conclusions: Penciclovir cream has demonstrated efficacy for a bread range of clinically important outcomes. Significant effects on lesion area, lesion symptoms, and other lesion attributes extend the clinical efficacy of penciclovir cream beyond lesion healing.
引用
收藏
页码:76 / 90
页数:15
相关论文
共 50 条
  • [1] Penciclovir cream for the treatment of herpes simplex labialis - A randomized, multicenter, double-blind, placebo-controlled trial
    Spruance, SL
    Rea, TL
    Thoming, C
    Tucker, R
    Saltzman, R
    Boon, R
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (17): : 1374 - 1379
  • [2] Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial
    Lin, L
    Chen, XS
    Cui, PG
    Wang, JB
    Guo, ZP
    Lu, NZ
    Bi, ZG
    Jia, H
    Yang, XY
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2002, 13 (02) : 67 - 72
  • [3] ORAL ACYCLOVIR AND HERPES LABIALIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    RABORN, GW
    MCGAW, WT
    GRACE, M
    TYRRELL, LD
    SAMUELS, SM
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1987, 115 (01): : 38 - 42
  • [4] Therapeutic effect of 1,5-pentanediol for herpes simplex labialis: a randomized, double-blind, placebo-controlled clinical trial
    Regina Busch
    Hans-Joachim Graubaum
    Joerg Gruenwald
    Jan Faergemann
    Advances in Therapy, 2009, 26 : 719 - 727
  • [5] Therapeutic effect of 1,5-pentanediol for herpes simplex labialis: a randomized, double-blind, placebo-controlled clinical trial
    Busch, Regina
    Graubaum, Hans-Joachim
    Gruenwald, Joerg
    Faergemann, Jan
    ADVANCES IN THERAPY, 2009, 26 (07) : 719 - 727
  • [6] A double-blind, placebo-controlled study of topical tetracaine in the treatment of herpes labialis
    Kaminester, LH
    Pariser, RJ
    Pariser, DM
    Weiss, JS
    Shavin, JS
    Landsman, L
    Haines, HG
    Osborne, DW
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (06) : 996 - 1001
  • [7] LongoVital® and herpes labialis:: a randomised, double-blind, placebo-controlled study
    Pedersen, A
    ORAL DISEASES, 2001, 7 (04) : 221 - 225
  • [8] n-Docosanol 10% cream in the treatment of recurrent herpes labialis: A randomised, double-blind, placebo-controlled study
    Habbema, L
    DeBoulle, K
    Roders, GA
    Katz, DH
    ACTA DERMATO-VENEREOLOGICA, 1996, 76 (06) : 479 - 481
  • [9] Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial
    Sacks, SL
    Thisted, RA
    Jones, TM
    Barbarash, RA
    Mikolich, DJ
    Ruoff, GE
    Jorizzo, JL
    Gunnill, LB
    Katz, DH
    Khalil, MH
    Morrow, PR
    Yakatan, GJ
    Pope, LE
    Berg, JE
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (02) : 222 - 230
  • [10] ORAL ACYCLOVIR TO SUPPRESS FREQUENTLY RECURRENT HERPES LABIALIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    ROONEY, JF
    STRAUS, SE
    MANNIX, ML
    WOHLENBERG, CR
    ALLING, DW
    DUMOIS, JA
    NOTKINS, AL
    ANNALS OF INTERNAL MEDICINE, 1993, 118 (04) : 268 - 272